Mayne Pharma generates multi-million-dollar annual revenues reflecting its position as an international specialty pharmaceutical enterprise. According to its full-year financial reporting, the company posted annual revenues of approximately $383.7 million, driven by stable commercial contributions from its core product portfolios, specialty dermatology brands, women's health therapeutics, and contract manufacturing services operating across its primary geographic markets in Australia and North America.